A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, lymph node positive breast cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Goserelin (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NEST
- 30 Sep 2013 Biomarkers information updated
- 13 Feb 2013 Planned end date changed from 1 Feb 2016 to 31 Mar 2016 as reported by Korean Clinical Trials Register record.
- 04 Jul 2012 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea: KCT0000460).